Sun Pharmaceutical Industries Limited — Updates, 07-04-2025: Press Release

Sun Pharmaceutical Industries Limited has introduced Fexuclue® (Fexuprazan), a novel potassium-competitive acid blocker, for treating Erosive Esophagitis in India. This new treatment demonstrates a fast onset of action and a stable suppression of gastric acid, with a half-life of nine hours, enabling effective control of nocturnal symptoms. Fexuprazan was successfully validated in a Phase 3 clinical study involving the Indian adult population, achieving over 95% healing of patients' erosive esophagitis by eight weeks.

Sun Pharma has secured the rights from Daewoong Pharmaceutical Co Ltd to manufacture and market Fexuclue® in India, which involves upfront payments and royalties as per their agreement. The launch reinforces Sun Pharma's commitment to addressing the unmet needs of patients with this condition, enhancing their quality of life. Investors should monitor the market reception and potential sales growth from this innovative product.